CTIS2024-514495-41-00招募中1 期
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS) - EFC16035
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 849
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- •18 to 55 years of age inclusive, Diagnosis of PPMS according to the 2017 McDonald criteria, Expanded disability status scale (EDSS) score between 2.0 to 6.5 points, at screening inclusive, Positive cerebrospinal fluid oligoclonal bands and/or elevated Immunoglobulin G (IgG) index either during screening or documented previous history., Contraceptive use consistent with local regulations for individuals participating in clinical studies, Participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: - Is not a woman of childbearing potential (WOCBP) or is a WOCBP and agrees to use an acceptable contraceptive method - the participant must not have access to ocrelizumab (eg, ocrelizumab not available on the national market or not reimbursed for the approved indication). - the participant must have access to and be eligible to be treated with ocrelizumab but: 1) does not tolerate it due to side effects or safety reasons; and/or 2) has failed ocrelizumab treatment due to perceived lack of efficacy
排除标准
- •Participant has conditions that would adversely affect study participation such as short life expectancy., A history of significant bleeding event within 6 months prior to screening, according to the Investigator’s judgment such as, but not limited to cerebral or gastrointestinal, Lymphocyte count below the lower limit of normal at Screening., Recent live (attenuated) vaccine within 2 months before the first treatment visit., Recent major surgery (within 4 weeks of Screening) or planned major surgery during the study., The participant has received medications/treatments for MS within a specified time frame., Receiving potent and moderate inducers of cytochrome P450 3A (CYP3A) or potent inhibitors of CYP2C8 hepatic enzymes., Receiving anticoagulant or antiplatelet therapy (such as aspirin >81mg/day, clopidogrel, warfarin)., Contraindications to magnetic resonance imaging (MRI)., Evidence of infection with human immunodeficiency virus (HIV), transplantation, progressive multifocal leukoencephalopathy (PML), active hepatitis B or C, active or latent tuberculosis or other active infection that would adversely affect study participation., Persistent chronic or active or recurring system infection that may adversely affect participation or IMP administration in this study as judged by the investigator, History of malignancy within 5 years prior to screening., History of alcohol or drug abuse within 1 year prior to Screening., Hospitalized for psychiatric disease within 2 years prior to Screening., Clinically significant laboratory abnormalities (including evidence of liver injury) or electrocardiogram abnormalities at Screening., A bleeding disorder or known platelet dysfunction at any time prior to the screening visit., A platelet count <150 000/µL at the screening visit.
研究者
相似试验
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-PTGenzyme Corporation1,700
进行中（未招募）
1 期
Primary progressive multiple sclerosis (PPMS) Study of Bruton's tyrosine kinase (BTK) inhibitor SAR442168 (PERSEUS)Primary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063401Term: Primary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000645-14-HUGenzyme Corporation1,320
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor tolebrutinib SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-FIGenzyme Corporation1,700
进行中（未招募）
3 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168Secondary Progressive Multiple SclerosisJPRN-jRCT2031200240Tanaka Tomoyuki1,290
进行中（未招募）
1 期
onrelapsing secondary progressive multiple sclerosis (NRSPMS) study of Bruton tyrosine kinase (BTK) inhibitor SAR442168 (HERCULES)on-relapsing Secondary Progressive Multiple SclerosisMedDRA version: 21.1Level: PTClassification code 10063400Term: Secondary progressive multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2020-000647-30-GBGenzyme Corporation1,700